Chemotherapeutic agents for inhibition of protein translation
AssigneeThe Royal University for the Advancement of Learning/McGill University
InventorsJerry Pelletier, Marie-Ève Bordeleau, Lisa Lindqvist, Robert Francis, Junichi Tanaka
Life of this patent
Estimating the term…
Abstract
The present invention relates to a anti-proliferative target for designing chemotherapeutic agents, which comprises a EIF4A protein having an amino acid sequence, as defined in claim 1.
Claims16
A method to treat a lymphoma in an individual in need thereof said method comprising:
- administering to said individual a chemotherapeutic agent selected from the group consisting of doxorubicin, daunorubicin, cyclophosphamide, methotrexate, paclitaxel and alkylating agents, and a composition comprising an effective amount of a compound of formula I, or II, and a pharmaceutically acceptable carrier,
- wherein
- R1, R2 and R3 are independently a hydrogen atom, a halogen atom, an oxygen atom of a ketone group, —OR4, —C(O)H, —CO2H, —C(O)R18, —NR11R12, —SH, C1-C10 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, —(CH2), C1-C10 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protected hydroxyl group,
- R4 and R18 are a hydrogen atom alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protecting group for a hydroxyl group;
- R11 and R12 are independently hydrogen, C1-C10 alkyl, C6-C12 aralkyl.
A method to treat lymphoma in an individual in need thereof, said method comprising administering a chemotherapeutic agent selected from doxorubicin and cyclophosphamide and a composition comprising an effective amount of a compound of formula I or II, and a pharmaceutically acceptable carrier,
- wherein
- R1, R2 and R3 are independently a hydrogen atom, a halogen atom, an oxygen atom of a ketone group, —OR4, —C(O)H, —CO2H, —C(O)R18, —NR11R12, —SH, C1-C10 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, —(CH2), C1-C10 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protected hydroxyl group,
- R4 and R18 are a hydrogen atom alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protecting group for a hydroxyl group;
- R11 and R12 are independently hydrogen, C1-C10 alkyl, C6-C12 aralkyl.
A method to treat lymphoma in an individual in need thereof, said method comprising administering doxorubicin and a composition comprising an effective amount of a compound of formula I or II, and a pharmaceutically acceptable carrier,
- wherein
- R1, R2 and R3 are independently a hydrogen atom, a halogen atom, an oxygen atom of a ketone group, —OR4, —C(O)H, —CO2H, —C(O)R18, —NR11R12, —SH, C1-C10 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, —(CH2), C1-C10alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protected hydroxyl group,
- R4 and R18 are a hydrogen atom alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C4-C10 cycloalkenyl, C6-C12 aralkyl, —C(O)H, or a protecting group for a hydroxyl group;
- R11 and R12 are independently hydrogen, C1-C10 alkyl, C6-C12 aralkyl.
A method to treat lymphoma in an individual in need thereof, said method comprising administering doxorubicin and a composition comprising an effective amount of hippuristanol.
Dependencies are inferred from the claim text.